2012-11-11 13:32:05 -

Clinical Trial Data to be Presented at The Liver Meeting(®) 2012 in Boston

BOSTON,  Nov. 11, 2012 -  GlobeImmune, Inc.,  today announced  Phase 2b clinical
data  showing that GI-5005, a Tarmogen(®) product candidate for the treatment of
chronic  hepatitis C virus (HCV) infection,  improved virologic clearance of HCV
in  combination with pegylated-interferon  plus ribavirin (P/R)  in genotype 1,
IL28B  T/T patients.  IL28B T/T is an unfavorable patient genotype that predicts
poor sustained virologic response (SVR24) to P/R.

GI-5005-02 is  a randomized Phase 2b clinical  trial evaluating GI-5005 plus P/R
compared  to  P/R  alone  in  subjects  with  chronic  genotype 1 HCV infection.
 Preliminary  data from the  trial   showed that  the largest improvement in SVR24
was  observed in subjects  with the most  difficult-to-treat IL28B T/T genotype.
GI-5005 enhanced   HCV-specific   cellular  immunity  and  improved  SVR24  [GI-
5005+P/R: 3/5 (60%) compared to P/R alone: 0/5 (0%)].

Following  this result, the trial was expanded to enroll and treat an additional
17 genotype  1, treatment-naïve subjects having the  IL28B T/T genotype.  In the
study,  presented by Dr.  M. L. Shiffman,  the Liver Institute  of Virginia, Bon
Secours  Virginia Health System,  Newport News, VA,  GI-5005 in combination with
P/R was well tolerated and had a higher end of treatment virologic response rate
[GI-5005+P/R; 10/16 (63%) compared to P/R alone; 3/11 (27%)].

"GI-5005 in combination with pegylated interferon + ribavirin appears to have an
effect  in the most difficult-to-treat IL28B  patients," said Dr. Shiffman. "GI-
5005 could  potentially be used in treatment refractory HCV patient subgroups in
future regimens."

GI-5005 contains a fusion of two hepatitis C proteins, NS3 and Core, which are
highly conserved across HCV genotypes and are recognized by T cells. GI-5005 is
engineered to activate an HCV-specific T cell immune response, resulting in the
reduction of cells containing viral antigens.

The World Health Organization estimates that up to 170 million people globally
are infected with HCV, with three to four million new infections each year.
Approximately 20% to 30% of all HCV patients will face life-threatening
complications as a result of their disease. In industrialized countries, HCV
accounts for 40% of cases of end-stage cirrhosis, 60% of cases of hepatocellular
carcinoma and 30% of liver transplants.

About GlobeImmune

GlobeImmune  is a  biopharmaceutical company  focused on  developing therapeutic
products for cancer and infectious diseases based on its proprietary Tarmogen(®)
platform. Tarmogens activate the immune system by stimulating cellular immunity,
known  as T cell immunity, in  contrast to traditional vaccines, which stimulate
predominately  antibody production.  To date,  Tarmogen product  candidates have
been   generally   well  tolerated  in  clinical  trials  for  multiple  disease
indications and are efficient to manufacture.   In May 2009, the company entered
into   a  collaboration  agreement  with  Celgene  Corporation  focused  on  the
discovery,  development  and  commercialization  of  product  candidates for the
treatment  of cancer.  In October  2011, the company  entered into  a worldwide,
strategic collaboration with Gilead Sciences, Inc., to develop Tarmogens for the
treatment  of chronic hepatitis B  infection. For additional information, please
visit the company's website at www.globeimmune.com.

                                     # # #

GLOBEIMMUNE CONTACT:

David Apelian, M.D., Ph.D.

SVP Research & Development and Chief Medical Officer

T: 303-625-2820

information@globeimmune.com


GLOBEIMMUNE MEDIA CONTACTS:

Lena Evans or Tony Russo, Ph.D.

Russo Partners LLC

T: 212-845-4262 or 212-845-4251

lena.evans@russopartnersllc.com

tony.russo@russopartnersllc.com







This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: GlobeImmune, Inc via Thomson Reuters ONE
[HUG#1656887]